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Antonetta Radu, B.S.,1 Jun-Ichiro Jo, Ph.D.,3 Michio Kaneko, M.D., Ph.D.,2
Yasuhiko Tabata, Ph.D., D.Pharm., D.Med.Sci.,3 and Alan Flake, M.D.1
Myelomeningocele (MMC) is a common and devastating malformation. As an alternative to fetal surgical repair,
tissue engineering has the potential to provide a less invasive approach for tissue coverage applicable at an
earlier stage of gestation. We have previously evaluated the use of gelatin hydrogel composites composed of
gelatin sponges and sheets as a platform for tissue coverage of the MMC defect in the retinoic acid induced fetal
rat model of MMC. In the current study, we compare our previous composite with gelatin microspheres as a
scaffold for tissue ingrowth and cellular adhesion within the amniotic fluid environment. We also examine the
relative efficacy of various bioactive protein coatings on the adhesion of amniotic fluid cells to the construct
within the amniotic cavity. We conclude from this study that gelatin microspheres are as effective as gelatin
sponges as a scaffold for cellular ingrowth and amniotic fluid cell adhesion and that collagen type I and
fibronectin coatings enhance amniotic fluid cell adhesion to the gelatin-based scaffolds. These findings support
the potential for the development of a tissue-engineered injectable scaffold that could be applied by ultrasound-
guided injection, much earlier and less invasively than sponge or sheet-based composites.
Introduction
Myelomeningocele (MMC) is one of the most com-mon congenital malformations and represents the
most severe form of Spina Bifida. MMC results from failure
of closure of the neural tube with secondary exposure of the
neural elements. A two-hit hypothesis has been proposed to
explain the neurological damage observed in children with
MMC.1 To prevent the second hit, that is, physical and
chemical damage to the spinal cord from exposure to the
intrauterine environment, prenatal closure of the MMC de-
fect has been experimentally and clinically investigated and
an NIH-sponsored clinical trial comparing prenatal closure
of the MMC defect with standard postnatal treatment is
currently underway (Management of Myelomeningocele
Study). Before the initiation of this trial, preliminary studies
documented a reversal of hindbrain herniation, a reduced
incidence of shunt-dependent hydrocephalus, and better-
than-anticipated lower extremity neuromotor function in a
subset of patients.2–9 However, many children after fetal
surgery have significant residual deficits. It is likely that
open fetal surgery is either performed too late to prevent
damage to the neural elements and/or the surgical proce-
dure itself may directly or indirectly cause neural damage.
Therefore, a less invasive approach that can be applied
earlier in gestation is needed to preserve maximal neural
function.
Toward that goal, we are investigating tissue engineer-
ing techniques to achieve tissue coverage of the MMC de-
fect. We have previously described the use of gelatin
hydrogel composites constructed by combining a gelatin
sheet and a gelatin sponge. Application of the composite to
the MMC defect in the rat model of retinoic acid (RA)-
induced MMC resulted in the induction of epidermal
ingrowth underneath the gelatin sponges, and cellular
adhesion over the gelatin sheet with associated deposition
of extracellular matrix (ECM).10 Gelatin hydrogel en-
gineered as shaped sheets or sponges appeared to be an
effective scaffold in the unique amniotic fluid-filled intra-
uterine environment and may be amenable to fetoscopic
application. However, an injectable scaffold would be
much less invasive and could potentially be applied much
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earlier in gestation under ultrasound guidance maximizing
the preservation of neural elements.11
The objective of this study was to evaluate whether gelatin
microspheres could provide an injectable scaffold with the
same properties as the previously described gelatin sponge
and sheet composite supporting epidermal ingrowth and
cellular adherence over the MMC defect. We also examine
whether bioactive proteins present in the ECM can enhance
cellular adhesion to the scaffold.
Materials and Methods
Biomaterials
Gelatin with an isoelectric point of 5.0 (Mw¼ 99,000 Da),
prepared through alkaline processing of bovine bone, was
kindly supplied by Nitta Gelatin Co. The bioactive proteins
used in this study were the following: collagen type I (BD
Biosciences); collagen type IV (Sigma-Aldrich); fibronectin
(EMD Chemical); laminin (Invitrogen).
Preparation of gelatin sponges
Gelatin sponges, microspheres, and sheets were prepared
by dehydrothermal crosslinking of gelatin prepared as pre-
viously described.10,12–14 For the gelatin sponge preparation,
a 3 or 7 w/v% gelatin aqueous solution was agitated at
5000 rpm for 3 min with a homogenizer (Auto cell master
CM-2000; AS ONE Co.) at room temperature, followed by
casting into a 6060 cm2 polypropylene dish. The homoge-
nized solution was frozen in liquid nitrogen for 20 s, frozen
at 208C for 12 h, and freeze-dried (TF5-85ATANN; Takara
Co.). The frozen gelatin sponges were dehydrothermally
crosslinked at 1608C for 12 h in a vacuum drying oven (DN-
30S; Sato Vac, Inc.). The crosslinked gelatin sponges were
punched out to obtain discs of 1 mm thickness and 3.5 mm
diameter and sterilized with ethylene oxide gas (EOG) (EOG
sterilizer SA-160; ELK Co.) (Fig. 1A).
Preparation of gelatin microspheres
Gelatin microspheres were prepared as previously de-
scribed.15 Briefly, 20 mL of 10 wt% gelatin solution preheated
at 408C for 1 h was added drop wise into 600 mL of olive oil
while stirring at 400 rpm for 10 min at 408C to prepare a
water-in-oil emulsion. The emulsion was cooled to 08C, and
stirring was continued for 30 min to complete the gelation of
the gelatin in the water phase. After addition of 200 mL of
acetone, the emulsion was further stirred at 200 rpm for
15 min. The resulting microspheres were washed four times
with acetone, collected by centrifugation (5000 rpm, for
5 min, at 48C), and suspended in acetone. The microspheres
were put through a sieve with an aperture of 32 or 20 mm,
followed by air-drying at 48C to obtain noncrosslinked gel-
atin microspheres. Microspheres were then put into a vac-
FIG. 1. Preparation of the gelatin scaffolds. (A) Gross appearance (Top) and cross-sectional scanning electron microscopy
images (Bottom) of gelatin hydrogel scaffolds. Far left: A sponge prepared at 3 w/v% gelatin (pore size¼ 200.22 33.31mm).
Scale bar value represents 500 mm. Left: A sponge prepared at 7 w/v% gelatin (pore size¼ 152.48 33.79 mm). Scale bar value
represents 500 mm. Right: The microspheres prepared at 10 w/v% gelatin (sphere size¼ 14.83 3.16 mm. Scale bar value
represents 100mm. Far right: A sheet prepared at 5 w/v% gelatin. (B) Left: A gelatin hat-shaped sheet containing gelatin
sponge and its schematic. Right: A gelatin hat-shaped sheet with the gelatin sponge glued externally and its schematic.
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uum drying oven at 1608C for 24 h and sterilized with EOG
(Fig. 1A).
Preparation of gelatin sheets
Hat-shaped gelatin sheets were prepared for the in vivo
experiments as previously described.10 Briefly, a 5 w/v%
solution of gelatin solution was poured between a bicom-
ponent mold, with corresponding elevated and recessed ar-
eas. The filled molds were kept in a refrigerator at 48C until
the gelatin solution was completely air dried. The molded
gelatin was peeled off of the cast and put into a vacuum
drying oven at 1608C for 24 h for crosslinking. The resulting
product was harvested by cutting around each of the sheets
to form 36 individual gelatin sheets that corresponded to the
shape of the MMC defect. The sheets were sterilized with
EOG. When epidermal ingrowth underneath the gelatin
scaffolds was examined, the gelatin sponges or microspheres
were put into the concave space of the hat-shaped gelatin
sheet to prepare a gelatin composite. When cell adhesion
onto the gelatin scaffolds was examined, gelatin sponges or
microspheres were glued on the outside of gelatin sheets
with cyanoacrylate adhesive (Instant KRAZY GLUE; Krazy
Glue) (Fig. 1B).
For the in vitro cell proliferation experiment, flat gelatin
sheets were prepared. A 5 w/v% of gelatin solution (5 mL)
was poured into a 100100 cm2 polypropylene dish and kept
in a refrigerator at 48C until the gelatin solution was com-
pletely air-dried. The dried gelatin was peeled off of the cast
and put into a vacuum drying oven at 1608C for 24 h for
crosslinking. The crosslinked gelatin sheet was punched out
to obtain 15-mm-diameter round sheets to fit a 24-well dish.
The sheets were sterilized with EOG.
Coating of gelatin sheets with bioactive proteins
Aqueous solutions of collagen type I, collagen type IV,
fibronectin, and laminin or phosphate-buffered saline (PBS,
pH 7.4) control (1 mg/mL, 50 mL) were applied to crosslinked
dry gelatin sheets and left overnight at room temperature to
allow complete absorption. The gelatin sheets coated with
proteins were used without PBS washing.
Estimation of in vitro degradation of gelatin scaffolds
Gelatin sponges or microspheres (10 mg) were put into
2 mL tubes with 750 mL of distilled water to allow them to
swell for 12 h, and then 750mL of 2N hydrochloric acid was
added. At different time intervals, 200 mL of solution was
sampled and 200 mL of fresh 1N hydrochloric acid was ad-
ded. The absorbance of solution of samples was measured at
a wave length of 260 nm by a UV-vis spectrophotometer
(Beckman Coulter, Inc.) to estimate the amount of gelatin
degraded.
In vitro cell culture on gelatin sheets coated
with bioactive proteins
Rat fetal fibroblasts were used as a cell source. Briefly,
after euthanasia, fetal skin was sterilely dissected from fetal
rats and placed on 10 cm culture dishes (Corning, Inc.). After
the skins became relatively dried and adherent to the culture
dish, Dulbecco’s modified Eagle’s medium (Gibco) supple-
mented with 10% fetal bovine serum (Gemini Bio) and 1%
penicillin–streptomycin (Cellgro) was added, and they were
incubated in 5% carbon dioxide (CO2) at 378C. Fibroblasts
started growing on around 7–10 days after harvest and the
skins were removed at 14 days. Fibroblasts were expanded
in culture and collected after two passages for use. Fifteen-
millimeter round gelatin sheets coated with bioactive pro-
teins were placed in 24-well dishes and 4104 fibroblasts
were placed on each gelatin sheet. Four samples were pre-
pared per each group. At serial time points gelatin sheets
were sampled and the viability of adherent cells on the
scaffolds was measured by the methylthiazol tetrazolium
(MTT)-based colorimetric assay kit according to its instruc-
tions (Cell Proliferation Kit I; Roche; MTT labeling reagent
10mL, solubilization solution 100mL, 650 nm wavelength).
Animal experiments
All experimental protocols were approved by the Institu-
tional Animal Care and Use Committee at The Children’s
Hospital of Philadelphia or the Committee on Animal Care
and Use at Kyoto University and followed guidelines set
forth in the National Institutes of Health Guide for Care and
Use of Laboratory Animals.
MMC defects in fetal rats were created based on the protocol
described previously.10,11 Briefly, time-dated Sprague-Dawley
rats (Charles River Laboratories or Shimizu Laboratory Sup-
plies Co.) were used for this study. After a brief exposure to
isoflurane (Abbott Lab), pregnant rats were fed 50 mg/kg of
all-trans RA (Sigma-Aldrich) dissolved in olive oil (10 mg/mL)
at embryonic day 10 (E10).
Organ culture of fetal rat MMC
RA-exposed Sprague-Dawley dams were euthanized by
CO2 inhalation followed by cervical dislocation at E22. The
fetuses with MMC were harvested, and the MMC lesion and
surrounding tissues were dissected. The gelatin scaffolds
were applied over the MMC and fixed with a cyanoacrylate
adhesive between the scaffold edge and surrounding skin.
The MMC explants were cultured in six-well plates with
Dulbecco’s modified Eagle’s medium supplemented with
10% fetal bovine serum and 1% penicillin–streptomycin
with 5% CO2 at 378C for 7 days. There were four experi-
mental groups: Group A—the MMC covered with gelatin
sponge prepared from 3 w/v% gelatin solution and 12 h
dehydrothermal crosslinking; Group B—the MMC covered
with the gelatin sponge prepared from 7 w/v% gelatin so-
lution and 12 h dehydrothermal crosslinking; Group C—the
MMC covered with gelatin microspheres prepared from
10 w/v% gelatin solution and 24 h dehydrothermal cross-
linking; Group D—the MMC covered with the gelatin sheet
prepared from 5 w/v% gelatin solution as a control.
Surgical procedure
RA-exposed Sprague-Dawley dams were anesthetized at
E18 with inhaled isoflurane. The uterine horns were exposed
through a maternal midline laparotomy. The uterine wall and
amniotic membrane were sutured with a 6-0 polypropylene
purse string suture (PDS-II; ETHICON). The back of each
fetus was exposed through a small hysterotomy created
within the purse string and a gelatin sheet or composite was
applied over the MMC area. The edge of the gelatin sheet was
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spot glued with a cyanoacrylate adhesive for better adhesion.
After the gelatin was securely fixed, the fetus was returned
into the uterus. The amniotic fluid was replaced with sterile
normal saline and the hysterotomy was closed with the purse-
string suture. The uterus was returned to the abdomen and
the incision closed in two layers with a 4-0 Vicryl running
suture (ETHICON). Four fetuses with MMC per dam were
manipulated. Dams were euthanized by CO2 inhalation fol-
lowed by cervical dislocation at E22 and the fetuses were
harvested by cesarean section. Analysis was dependent upon
the experimental groups. Groups A, C, and D had constructs
applied as described for the in vitro MMC organ culture above
and underwent analysis for epidermal ingrowth and cellular
adhesion. MMCs that were covered with gelatin sheets coated
with bioactive proteins (collagen type I, collagen type IV, fi-
bronectin, laminin, and PBS control) were assessed for cellular
adhesion alone.
Histological analysis
Cultured MMC explants and operated whole fetuses were
fixed in 10% neutral buffered formalin (Sigma-Aldrich) and
decalcified using Immunocal (Decal chemical corp.) for 7–10
days. After histoprocessing, they were embedded in paraffin
wax and sectioned at 4 mm thickness. Sections were dewaxed,
serially rehydrated, and stained with eosin and hematoxylin.
Sections assigned for immunohistochemistry were air-dried
overnight in a 508C incubator, deparaffinized, and rehy-
drated in distilled water. To block endogenous peroxidase,
slides were incubated for 30 min with 3% hydrogen peroxide
solution (Sigma-Aldrich). The sections were then immersed
in antigen unmasking solution (pH 6.0; Vector Laboratories)
and microwaved (Ted Pella) for 4 min on high power, cooled
at room temperature for 30 min, washed in distilled water,
and transferred to PBS containing 0.1% Triton X-100. The
following primary antibodies were used: antivimentin (In-
vitrogen; prediluted); anti-panCytokeratin (Abcam, Cam-
bridge, MA; 1:100); antidesmin (Invitrogen; prediluted);
antismooth muscle actin (DAKO; 1:100); anti-CD31 (BD
Biosciences; 1:25).
Primary antibodies were diluted using ready-to-use An-
tibody diluent (DakoCytomation Denmark A/S), and ap-
plied over the slides and then incubated over night at 48C.
On the following day, the sections were washed three times
with PBS containing 0.1% Triton X-100 and then incubated
with horseradish peroxidase (HRP) polymer conjugate broad
spectrum (DAB) (SuperPicture, ZYMED Laboratories, Inc.)
for 30 min at room temperature. Finally, the sections were
washed one time with PBS containing Triton X-100, observed
using Peroxidase Substrate Kit (DAB, Vector Laboratories,
Inc.), counterstained with hematoxylin, dehydrated, and
mounted using Permount (Fisher Scientific). If necessary, the
images were merged into a single image, using an Apple
Macintosh computer (Mackintosh) with Adobe Photoshop
Elements 2.0 (Adobe).
Assessment of epidermal ingrowth
As a measure of role of gelatin scaffolds in cell growth, the
distance between the original keratinized epidermis and the
edge of epidermis at the site of applied gelatin scaffolds was
measured to assess the epidermal ingrowth underneath the
scaffolds using a Windows XP computer (Microsoft Co.)
with Axio Vision 4.5 (Carl Zeiss MicroImaging, Inc.).
Evaluation of cellular adhesion on gelatin scaffolds
To evaluate cell adhesion on the gelatin scaffolds, mea-
surement of viability of adherent cells was performed. Just
after euthanasia, adherent gelatin scaffolds were removed
from fetal body. The edge of gelatin sheet was removed to
eliminate the contamination of glued fetal body tissue. The
trimmed gelatin scaffold was placed in a 48-well culture dish
and cellular viability was measured using the MTT-based
colorimetric assay kit according to the kit instructions (Cell
Proliferation Kit I; MTT labeling reagent 20mL, solubilization
solution 200mL, 650 nm wavelength).
Statistical data analysis
SPSS (Version 18: SPSS, Inc.) was used for statistical
analysis. Data were first analyzed for normality of distribution
using a Shapiro-Wilk test. For non-normally distributed data,
differences between groups were determined using a Kruskal-
Walls test, and Mann-Whitney post hoc tests to identify differ-
ences between individual mean values. Normally distributed
data were analyzed using a one-way analysis of variance.
When variance of data was homogeneous, as determined by
Levenes test, post hoc analysis was performed using the least
significant difference test. When variance of data was inho-
mogeneous, the Tamhane post hoc test was used to identify
significant differences between individual means. Statistical
significance was accepted at p< 0.05. All data are expressed as
means the standard deviation.
Results
Preparation and characterization of gelatin scaffolds
Table 1 summarizes the preparation methods utilized and
characterization of each gelatin scaffold. In an attempt to
standardize our scaffolds so that the primary variable
would be scaffold shape, we tested the in vitro degradation
of each scaffold to confirm similar degradation characteris-
tics in 1N hydrochloric acid assay. Figure 2 demonstrates the
time course of in vitro gelatin scaffold degradation. The ki-
netics of degradation to complete dissolution varied slightly
between scaffolds but all were completely dissolved in 12 h,
irrespective of the crosslinking conditions and scaffold
shape.
Epidermal ingrowth in organ culture
Figure 3A shows cross-sectional images of gelatin scaf-
folds on MMC after 7 days of in vitro organ culture. Figure 3B
demonstrates the epidermal ingrowth underneath the scaf-
folds. Compared with the gelatin sheet control (Group D;
22.22 20.90mm), significantly increased epidermal in-
growth was observed in the two sponge groups (Group A
and B; p< 0.05). The sponge with larger pore size (Group A)
(73.06 32.91mm) showed greater epidermal ingrowth than
the sponge with the smaller pore size (Group B)
(53.89 12.12mm) ( p< 0.05). The extent of epidermal
ingrowth for Group C (microsphere) (53.98 24.62mm) was
similar to that of Group B, but much greater than that of
Group D (sheet) ( p< 0.05).
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Epidermal ingrowth in vivo after fetal surgery
Figure 4A shows cross-sectional images of gelatin scaf-
folds covering the MMC defect 4 days after application
by open fetal surgery as well as an image of a non-
treated MMC defect. Advancement and morphological
changes of the epidermal edge were observed in all experi-
mental groups, compared to nontreated MMC. Figure 4B
shows a graph quantifying the degree of epidermal ingrowth
underneath the scaffolds. Epidermal ingrowth extended
71.22 19.91mm underneath the sponges (Group A) and
66.38 19.79mm under the microspheres (Group C), which
was significantly greater than that of the gelatin sheets
(Group D) (8.96 10.96mm) ( p< 0.05). There was no signif-
icant difference between Group A and Group C.
Cell adhesion to the outside of the gelatin
scaffold in vivo
Figure 5A shows cross-sectional images of cell adhesion
with associated ECM coating the outside of the gelatin
scaffolds 4 days after application of the gelatin scaffolds to
the MMC defect in vivo. The total number of adherent cells
as evaluated by the MTT cellular proliferation assay is shown
in Figure 5B. Significantly increased cell adhesion was ob-
served in the sponge and microsphere groups (Group
A; 84.54 50.47103 and Group C; 84.93 16.41103)
compared to the gelatin sheet control (Group D;
34.43 14.66103, p< 0.05).
Cell adhesion and proliferation on gelatin sheets
coated with bioactive proteins in vitro cell culture
The proliferation of cells adherent to gelatin sheets coated
with the various bioactive proteins in in vitro cell culture is
shown in Figure 6. Cells became confluent around day 12
and then regressed in the collagen type I, collagen type IV,
and fibronectin groups. Among the different bioactive pro-
teins the number of cells at confluence was greater in the
collagen I and fibronectin groups than collagen IV. In con-
trast, cells grew very slowly in the laminin and PBS groups
and did not reach confluence by day 15.






























7 w/v% 12 160 12 152.48 33.70 1.78106
C Micro
sphere
10 w/v% 24 160 12 14.83 3.16 1.78106
D Sheet 5 w/v% 24 160 12 1.0108
Details of preparation of gelatin scaffolds of each group and their morphologic characteristics.
CL, cross-linked.
FIG. 2. In vitro degradation
profile of gelatin scaffolds.
In vitro time profiles of gelatin
scaffold degradation. (^)
The gelatin sponges prepared
at 3 w/v% gelatin. (&) The
gelatin sponges prepared at
7 w/v% gelatin. (~) The
microspheres prepared at
10 w/v% gelatin. The sponges
and microspheres underwent
dehydrothermal crosslinking
for 12 and 24 h, respectively.
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Cellular adhesion to gelatin sheets coated
with bioactive proteins in vivo
Figure 7 shows the number of cells adherent to gelatin
sheets coated with different bioactive peptides in vivo after
application by fetal surgery. Collagen I (10.54 4.65104) and
fibronectin coating (7.32 1.61104) resulted in a significantly
higher number of adherent cells than the other bioactive pro-
teins (collagen IV; 5.05 1.38104, laminin; 3.27 0.58104,
and PBS; 2.63 0.85104, p< 0.05). There were no significant
differences between the collagen I and fibronectin groups or
between the collagen IV, laminin, and PBS groups.
Histological evaluation of adhered cells to the gelatin
sheet coated with bioactive proteins
Figure 8 shows histology of the cells and ECM coating the
outside of the gelatin sheets. Cells and ECM were observed
as either multiple layers or a thick single layer. Many cells
stained positively for smooth muscle actin and some cells
stained positively for pancytokeratin and vimentin. There were
no cells expressing desmin or CD31. These findings were seen
in all groups irrespective of the bioactive protein coatings.
Discussion
The primary requirement for a tissue engineering solution
to prenatal coverage of MMC is the generation of a me-
chanically stable, amniotic fluid impermeable tissue layer
over the MMC to protect the exposed neural elements from
chemical and physical injury. The application of tissue en-
gineering in the intrauterine environment presents unique
obstacles and opportunities. The fetus has unique regenera-
tive capacity with a higher frequency of stem cells in all
tissues and higher cell proliferation rates, as evidenced by the
remarkable ability of the early gestational fetus to heal
wounds without scar formation.16 Thus, an attractive ap-
proach is to utilize scaffolds and bioactive molecules to
stimulate endogenous fetal stem cells to regenerate a tissue
layer over the MMC similar to the approach used for
regeneration of skin defects or corneal wound healing.17,18 In
our previous study, a natural biodegradable biomaterial,
FIG. 3. Epidermal ingrowth under the gelatin scaffolds after 7 days of in vitro organ culture. (A) Representative cross-
sectional images of epidermal ingrowth beneath the scaffold after in vitro organ culture in each group. Group A: The MMC
covered with the gelatin sponge prepared from 3 w/v% gelatin solution and 12 h dehydrothermal crosslinking. Group B: The
MMC covered with the gelatin sponge prepared from 7 w/v% gelatin solution and 12 h dehydrothermal crosslinking. Group
C: The MMC covered with the gelatin microspheres prepared from 10 w/v% gelatin solution and 24 h dehydrothermal
crosslinking. Group D: The MMC covered with the gelatin sheet prepared from 5 w/v% gelatin solution as a control. The
arrow indicates the measured distance of epidermal ingrowth between the original keratinized epidermis and the edge of
epidermis. Magnification:10. (B) Bar chart of epidermal ingrowth for each group. ( ): significant difference versus Group
A: p< 0.05 (#): significant difference versus Group B: p< 0.05 (O): significant difference versus Group C: p< 0.05. MMC,
myelomeningocele. Color images available online at www.liebertonline.com/ten.
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gelatin hydrogel, was selected as the tissue engineering
scaffold for fetal MMC due to the advantages of cyto-
compatibility, easy formulation into various shapes, the
ability to control degradation, and its properties for protein
release.12,19,20 We demonstrated that gelatin sponges could
support cellular and epidermal ingrowth by endogenous
cells with the associated production of ECM even in the
amniotic fluid environment. Neovascularization was also
observed within the sponges, particularly with bFGF incor-
poration, supporting the potential for generation of sustain-
able tissue coverage and the ability of the scaffold to release
exogenous growth factors in the intrauterine environment.10
These findings were in good accordance with previously
reported wound healing studies utilizing gelatin hydro-
gel.14,18,21–23 If the MMC defect can be covered by neo-
epidermal or other types of tissue derived from ingrowth of
native cells, it would likely provide the necessary protection
against amniotic fluid exposure. In this in vivo study, the
calculated percent of closure by epithelial ingrowth of the
MMC defects was 25.03 10.49% in the sponge group
(Group A) and 22.31 9.34% in the microsphere group
(Group C) compared to only 2.69 6.93% in Group D
(sheets) at the time of harvest (4 days after scaffold appli-
cation). We beleive that this is promising; however, a large
animal model will be necessary to obtain longer term data
and to assess whether complete coverage is achieved. Future
results may be improved by incorporating growth factors
into the scaffolds to accelerate epidermal or other types of
cellular ingrowth.
Another unique opportunity presented by the intrauterine
environment is the presence of multi- or pluripotent stem
cells within the amniotic fluid.24–28 Thus, a second attractive
approach would be to develop methods to promote the ad-
herence of these cells to either the MMC itself, or a tissue-
engineered scaffold covering the MMC, so that they might
contribute to the generation of a tissue layer. In fact, the
finding of cell adhesion with ECM deposition along the
outside of the gelatin composite was observed in our study.
This is a phenomenon that was not mentioned in other
studies of tissue engineering for fetal MMC.29–32 The cells
FIG. 4. Epidermal ingrowth under the gelatin scaffolds 4 days after MMC coverage by fetal surgery. (A) Representative
cross-sectional images of epidermal ingrowth underneath the scaffolds in vivo for each group. Group A: The MMC covered
with the gelatin composite of a 12 h dehydrothermal crosslinked sponge prepared from 3 w/v% gelatin solution and a gelatin
sheet. Group C: The MMC covered with the gelatin composite of 24 h dehydrothermal crosslinked microspheres prepared
from 10 w/v% gelatin solution and a gelatin sheet. Group D: The MMC covered with only a gelatin sheet, and the nontreated
MMC as a control. The arrow indicates the measured distance of epidermal ingrowth between the original keratinized
epidermis and the edge of epidermis under a gelatin scaffold. The star marks demonstrate the position of the edge of the
original epidermis. Magnification: 10. (B) Bar chart of epidermal ingrowth for each group. ( ): significant difference
between the groups: p< 0.05. Color images available online at www.liebertonline.com/ten.
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adherent to the gelatin scaffolds seemed to derive from
amniocytes in our study, not from endogenous fetal cells.
They were composed of both epithelial and nonepithelial
cells, which were different from the cells that migrated into
the sponges from the fetal tissues that were composed of
only nonepithelial cells. In addition, the cell surface markers
of the adherent cells were very similar to that of the amniotic
fluid cells reported by others,27,28 especially mesenchymal
stromal cells. Finally, when exogenous cells were injected
into amniotic fluid, we observed similar adherence to the
gelatin sheet of the composite (data not shown). The ap-
pearance of the adherent cells and associated ECM varied
widely between experiments. A heterogeneous ECM with
sparse cells covering gelatin scaffold were seen on some
MMCs, whereas multiple dense cell layers could be observed
over the gelatin scaffold in other samples. This is not sur-
prising because of the brief duration of our in vivo experi-
ments and the variation in composition of amniotic fluid
cells. However, these cells seem to have potential as a cell
source for tissue coverage over the MMC, but further studies
in a large animal model that would allow a longer duration
of observation are needed. In addition, there may be strate-
gies to enhance the adherence and growth of amniotic fluid
cells or to add exogenous cells that might selectively target
the MMC sac.
The optimal scaffold material would provide endogenous
cells and amniotic fluid-derived cells with a local environ-
ment that promotes adhesion, proliferation, and differentia-
tion.22 Biomaterial scaffolds providing a modifiable platform
to optimize these events have a variety of designs, includ-
ing33 sheets,34,35 sponges,36 tubes,37 and nano/micro carri-
ers.38 From a clinical perspective the design of the scaffold
greatly influences the mode and potential timing of prenatal
application. The use of sheet or sponge scaffolds dictates
surgical placement by either open fetal surgery or fetoscopic
technique, both of which are technically feasible only at later
gestational ages (after 18–20 weeks of gestation). However, a
scaffold that could be injected under ultrasound guidance
onto the MMC defect would allow treatment at a much
earlier stage of development, potentially as early as the
MMC can be diagnosed (14–15 weeks gestation). We have
considered several injectable scaffold designs, including
particles, spheres, in situ forming materials, in situ cross-
linkable systems, thermogelling systems, and self-assembling
FIG. 5. Cell adhesion with ECM deposition along the outside of the gelatin scaffolds 4 days after application by fetal
surgery. (A) Representative cross-sectional images of cell adhesion associated with ECM outside of the gelatin scaffolds in
each groups. Group A: The MMC covered with a gelatin composite composed of a 12 h dehydrothermal crosslinked sponge
prepared from 3 w/v% gelatin solution and a gelatin sheet. Group C: The MMC covered with the gelatin composite com-
posed of 24 h dehydrothermal crosslinked microspheres prepared from 10 w/v% gelatin solution and a gelatin sheet. Group
D: The MMC covered with only a gelatin sheet. Magnification:20. (B) Bar graph of the total number of adherent cells on the
outside of the gelatin scaffolds. ( ): significant difference between the groups: p< 0.05. ECM, extracellular matrix. Color
images available online at www.liebertonline.com/ten.
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systems.33,38 Among these choices, microspheres that have
been widely used as a drug delivery systems33,38 were cho-
sen for ease of manufacture and because we could make
gelatin hydrogel microspheres for direct comparison with
our previously tested composite scaffolds for support of cell
growth and proliferation as well as amniotic fluid cell
adherence.
Ideally, microspheres as a scaffold material could be tested
by injection into amniotic cavity. However, at this point, we
have no technology that allows adherence of the micro-
spheres to the MMC and prevents dissolution of the micro-
spheres in the amniotic fluid. Before addressing this obstacle,
we wished to establish proof in principle that gelatin hy-
drogel microsphere-based scaffold design could support cell
ingrowth and adherence as well as our previous sheet and
sponge composite scaffolds.10 A gelatin composite was con-
structed with a hat-shaped gelatin sheet and either a sponge
or microspheres insert. The hat-shaped gelatin sheet conforms
to the MMC lesion and holds the microspheres in place over
the MMC preventing their dispersion. In this study, to ex-
amine the effect of the scaffold on epidermal ingrowth un-
derneath the scaffold, the sponges or microspheres were
placed underneath the gelatin sheet against the MMC defect.
To examine amniotic fluid cellular adhesion, the sponges or
microspheres were glued to the outside of the gelatin sheets.
In this study, we wished to compare the effects of scaffold
form, that is, sponge, microsphere, and sheet, as directly as
possible. Gelatin scaffold is a biodegradable material and its
degradation kinetics are determined by many factors, such as
the type of gelatin hydrogel, isoelectric point, gelatin con-
centration, scaffold shape, and the method and strength of
crosslinking. We reasoned that an appropriate standardiza-
tion of these parameters to allow direct comparison of the
effects of shape alone would be to select scaffolds of different
shapes with similar degradation profiles. We selected a pe-
riod of in vitro degradation (12 h in 1 N HCL) that in previous
studies correlated with an in vivo degradation period of over
4 days,12,19,20 allowing preservation of the morphology of the
construct over the duration of our study.
In addition, we utilized two models to compare the
scaffolds, an in vitro organ culture system39,40 and our
in vivo fetal surgery model. For in vitro organ culture we
determined that the epidermal ingrowth was no different
whether MMC defects from E20, E21, or E22 fetuses were
used. Since the skin and neural tissues of fetuses at less than
E22 were very fragile and difficult to manipulate, we used
E22 defects for our experimental studies. We also deter-
mined that significant differences were noted between our
scaffolds at 3 and 7 days of organ culture but not at 10 and
14 days in our pilot studies. We therefore used 7 days as our
experimental endpoint. Finally, while the in vitro organ
culture appeared similar to the in vivo model with respect to
epidermal ingrowth, we did not detect the cellular migra-
tion of native tissue into the sponges and angiogenesis seen
in the in vivo studies10; therefore, the in vitro organ culture
system was only used for evaluation of epidermal in-
growth.
We hypothesized that the gap space between micro-
spheres would mimic the porosity of sponges with respect to
support of cellular and epidermal ingrowth. Therefore, in
this study, gelatin microspheres (14.83 3.16 mm in diameter
dry and 47.98 22.22 mm in diameter in water) were com-
pared with gelatin sponge constructs with large pores
(200.22 33.31mm dry and 226.78 35.04mm in water) or
gelatin sponges with small pores (152.48 33.79mm dry and
189.34 26.87mm in water) and gelatin sheets without any
pore structure in vitro. The larger pore sponge proved su-
perior in vitro, so it was selected for the in vivo studies.
Theoretically, the calculated effective surface area among
10 v/w% microspheres, 3 v/w% sponges (big pores), and
7 v/w% sponges (small pores) are remarkably similar
(1.78106mmm2, 1.78106 mmm2, 1.78106mmm2 per 1.00
FIG. 7. Cell adhesion on gelatin sheets coated with various
bioactive proteins in vivo 4 days after application by fetal
surgery. Bar chart of the number of cells adherent to gelatin
sheets coated with different bioactive proteins assessed 4
days after application of gelatin sheets in vivo. ( ): signifi-
cant difference versus collagen type I: p< 0.05 (#): significant
difference versus fibronectin: p< 0.05.
FIG. 6. Cell adhesion and proliferation on gelatin sheets
coated with various bioactive proteins after up to 15 days of
in vitro cell culture. Graph of the proliferation of cells ad-
herent to gelatin sheets coated with bioactive proteins at
serial time points of in vitro cell culture evaluated by me-
thylthiazol tetrazolium cellular proliferation assay.
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106 mmm2), and much higher than sheets (1.00106 mmm2).
Also, the scaffolds chosen for this study appeared to remain
as expected histologically. Thus, we feel that the differences
noted in this study are primarily the result of the different
structural characteristics of the scaffolds. Our results dem-
onstrate that gelatin sponges and microspheres were similar
in their ability to support epidermal ingrowth and cell ad-
hesion, and that both were significantly better than gelatin
sheets alone. These results are consistent with previous
studies demonstrating that greater surface area and porosity
of a scaffold support cell adhesion and proliferation, and that
the approximate pore size of our 3 v/w% sponge is optimal
for tissue ingrowth.41,42 Microgeometric properties of the
sponge and microsphere surfaces also explain the difference
as roughened surfaces tend to promote greater cell adhesion
and growth than smooth surfaces.43
In general, artificial ECM constructs have been synthe-
sized from either naturally occurring molecular polymers or
synthetic polymers. Cell adhesion on scaffolds can poten-
tially be enhanced by combining ECM-derived peptides such
as Arg-Gly-Asp in fibronectin, Gly-Pro-Hyp in collagen type
I, (a1)2-a2 in collagen type IV, and Tyr-lle-Gly-Ser-Arg and
lle-Lys-Val-Ala-Val in laminin. All of these ECM-derived
proteins have been widely used to improve scaffold cell
adhesion, migration, proliferation, and ECM synthesis44 with
the primary goal of increasing similarity of the scaffold to
native tissue.45–47 In this study, ECM-derived proteins were
applied to gelatin sheets, not to gelatin microspheres, to
observe the direct effect of ECM-derived proteins on gelatin
scaffolds with the presumption that the same effect should
be observed on all gelatin hydrogel-based scaffolds. In our
study, the amniotic cells that adhered to gelatin scaffolds
were composed of mixture of epithelial cells and non-
epithelial cells that did not express myogenic or endothelial
markers. These cells were the same in all experimental
groups irrespective of the type of coating bioactive proteins.
However, more cell adhesion was seen in groups coated with
collagen type 1 and fibronectin, which is in agreement with
other studies.48–50 This makes sense because collagen type 1
and fibronectin are major ECM constituents in epithelial
tissues.
A major limitation of this study is relatively short ges-
tation of rat model and nonsurvivability of the pups. This
prevents any long-term assessment of whether or not du-
rable tissue coverage is achieved. Nevertheless, the present
study is encouraging and demonstrated gelatin micro-
spheres could support cellular adhesion and epidermal
proliferation and that they were equivalent to a sponge
scaffold in all respects. This supports our hypothesis that
gelatin microspheres might be a suitable starting material
for development of an injectable scaffold that would facil-
itate a truly minimally invasive approach for coverage of
fetal MMC. In further studies we hope to develop tech-
niques to promote adherence of microspheres to each other
and to the MMC defect to allow injection into the amniotic
fluid over the MMC defect without dispersion. These
techniques may involve positive-negative charge interac-
tions, specific molecular binding to ligands on the MMC sac
and/or the microspheres, and/or the use of hydrophobic
adhesives. Also, these results suggest that utilization of
collagen type I and fibronectin coating would increase cel-
lular adhesion to the scaffold in the fetal amniotic fluid
environment, accelerating coverage of the MMC defect. We
speculate that growth factors could be incorporated into the
gelatin microspheres to further support cell growth and
proliferation to optimize this approach.33 Although further
FIG. 8. Immunohistochemical analysis of the adherent cell layer to gelatin sheets coated with various bioactive proteins 4
days after application by fetal surgery Representative sections of the adherent cell layer and associated ECM on the outside of
the gelatin sheets. The staining did not differ between types of bioactive proteins, and all images are from sheets coated with
collagen type I. Magnification:20. Immunohistochemical staining for (A) H&E, (B) pancytokeratin, (C) vimentin, (D) alpha
smooth muscle actin (E) desmin, and (F) CD-31. Color images available online at www.liebertonline.com/ten.
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material and technological development is needed, the
present data strongly support the future potential of a less
invasive tissue engineering approach for prenatal coverage
of MMC.
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